Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial to Investigate the Correlation Between UGT1A1 Genotype and Irinotecan (CPT-11) Pharmacokinetics and Toxicity in Cancer Patients
Conditions
Interventions
irinotecan hydrochloride
Locations
1
United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Start Date
January 1, 1999
Primary Completion Date
October 1, 2003
Last Updated
January 24, 2013
NCT07388563
NCT06561048
NCT04195633
NCT04925609
NCT03278782
NCT03602157
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions